Opendata, web and dolomites


A novel approach of organ preservation using anti-necrosis agent before transplantation.

Total Cost €


EC-Contrib. €






Project "ELAPHARMA" data sheet

The following table provides information about the project.


Organization address
address: DULTSIN ST 16/6
city: TEL AVIV
postcode: 6936049
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2019-12-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ELA PHARMA LTD IL (TEL AVIV) coordinator 50˙000.00


 Project objective

One of the most important advances in organ transplantation has been the development of preservation procedures resulting in high quality and efficacy of organ supply and operations. However, current methods used to preserve organs are limited to a very short period of time (i.e. less than 24h). And insufficient organ preservation capabilities place important logistical limitation to organ donation which place several constraints on the distance that can be travelled to recover donor transplant. With such supply constraints, a great many of organs are wasted meanwhile, only 10 % of people on the waiting list received an organ and 18 people on waiting lists die every day across Europe due to the shortage of available organs. Overcoming the logistical constraints is an necessity to increase the availability of organs for donation by increasing the delivering area, reducing organ shortage and saving more lives.

To address the unresolved challenge ElaPharma has come with a new solution: A small additive molecules inhibiting an intracellular enzyme involved in organ necrosis processes during preservation. Intended for the flushing of organs at the time of organ removal from the donor in preparation for storage and transportation, ElaPharma anti-necrosis agent successfully maintain any organs for up to 24h suppressing all the supply constraints to organ replacement. Besides, after the 24h, organs preserved with ElaPharma have 8x higher cellular viability providing better patient outcomes and remission after transplantation. ElaPharma implementation will results in more lifesaving significantly increasing the organ delivering area, saving life by providing more transplantations. We expect to acquire 40% of the European market (i.e. 13 500 transplantations) and 7% of the US market (i.e. 2500 transplantations) by 2026. With this market shares we will reach €50.4 million revenues in 2026, with €20.37 million profit (ROI of 7.2). And we foresee to create 20 new jobs by 2026.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ELAPHARMA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ELAPHARMA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

HUD (2018)


Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More